Maharashtra FDA Chief Exposes 2800% Profit Hike on IV Sets, Demands Action
GS3Economy · S&T · Environment · Security· Industry, investment & MSMEs· Prelims + Mains·
Price transparency and regulatory intervention in medical devices: a GS3 and Ethics case study.
Why in news
Maharashtra FDA Commissioner Tukaram Mundhe exposed a 2800% profit margin on IV sets and requested the National Pharma Pricing Authority to intervene against excessive mark-ups on medical devices.
Background
A market survey by the Maharashtra State Price Monitoring Resource Unit revealed mark-ups up to 29 times procurement costs for essential medical devices. Specifically, an 'Medifusion IV set' purchased at Rs 11.05 was sold at Rs 325, resulting in a 2841% profit margin.
Facts for Prelims
- FactMaharashtra State Price Monitoring Resource Unit conducted the survey on medical device pricing.
- PostTukaram Mundhe is the Maharashtra FDA Commissioner.
- BodyNational Pharma Pricing Authority is the body requested to intervene on pricing disparities.
- FactThe 'Medifusion IV set' showed a profit margin of 2841% based on a purchase price of Rs 11.05 and an MRP of Rs 325.
Prelims practice question
With reference to the pricing of medical devices in Maharashtra, consider the following statements:
- The Maharashtra FDA Commissioner requested the National Pharma Pricing Authority to intervene against excessive mark-ups.
- The Medifusion IV set showed a profit margin of 2841% based on a purchase price of Rs 11.05.
- The Maharashtra State Price Monitoring Resource Unit revealed mark-ups of up to 10 times procurement costs.
Which of the statements given above is/are correct?
- (a)1 only
- (b)1 and 2 only
- (c)1 and 3 only
- (d)2 and 3 only
Show answer
Answer: (b) 1 and 2 only — Statements 1 and 2 are correct. Statement 3 is incorrect: The survey revealed mark-ups up to 29 times procurement costs.
For Mains
Q. Discuss the necessity of a robust regulatory framework for pricing essential medical devices to ensure equitable healthcare access and prevent exploitative commercial practices.
Dimensions to cover in your answer
- Market failure: Information asymmetry between manufacturers and consumers regarding procurement costs vs MRP
- Regulatory gap: Need for standardized price ceilings on non-scheduled essential medical consumables
- Ethical trade-offs: Balancing corporate profit incentives with the constitutional right to affordable healthcare
Keywords: Price Transparency · Market Distortion · Regulatory Intervention · Healthcare Affordability · Information Asymmetry
More Economy notes
- Fitch Raises India's GDP Growth Projections To 6.9% For This Fiscal Year · 23 September 2026
- RBI warns banks against a loan price war · 23 September 2026
- WACR tops repo rate for first time in nearly 2 months · 23 September 2026
- Adani Group firms settle Sebi case on governance issues · 23 September 2026
- Inside SEBI's AI War Room Tracking Suspicious Trades In Real Time · 22 September 2026
- 23 firms race to launch IPOs worth Rs 40,775 crore before September 30 deadline · 22 September 2026
Something wrong, or something missing?
Spotted a mistake in a note, or want a topic, format or PDF that would help your preparation? Write to us. We read every mail and fix errors fast.
Report a mistake →Ask for something →thesatyadheesh@gmail.com
This note is generated automatically from SatyaDheesh's news feed and mapped to the UPSC CSE syllabus. Check facts against the original report or PIB before using them in an answer.